Drug Profile
HCP 1105
Alternative Names: HCP1105Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Hyperlipidaemia
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for phase-I development in Hyperlipidaemia(Combination therapy, In volunteers) in South Korea (PO, Capsule)
- 01 Oct 2016 Hanmi Pharmaceuticals completes a phase I trial in Hyperlipidaemia (Combination therapy, In volunteers) in South Korea (NCT02941796)
- 01 Jul 2016 Phase-I clinical trials in Hyperlipidaemia (In volunteers, Combination therapy) in South Korea (PO) (NCT02941796)